A Phase I Study of SEA-TGT Immunotherapy in People with Classical Hodgkin Lymphoma

Share

Full Title

A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies

Purpose

The purpose of this study is to assess the safety of the investigational drug SEA-TGT in people with classical Hodgkin lymphoma that has come back or continued to grow despite treatment. SEA-TGT is an antibody that blocks a protein called TIGIT, which is found on T cells (a type of immune cell).

Certain types of cancer cells grow and survive by increasing the activity of TIGIT to “silence” the immune system. By blocking TIGIT, SEA-TGT may activate the immune system, allowing T cells to find and attack cancer cells. SEA-TGT is given intravenously (by vein).

Eligibility

To be eligible for this study, patients must meet several requirements, including:

  • Participants must have classical Hodgkin lymphoma that has come back or continued to grow despite prior treatment.
  • The serious side effects of previous therapies must go away before SEA-TGT is given.
  • Patients must be physically well enough that they are able to be mobile, take care of themselves, and engage in all but physically strenuous activities. For example, they must be well enough that they could carry out office work or light housework.
  • This study is for people age 18 and older.

Contact

For more information and to ask about eligibility for this study, please contact the office of Dr. Alison Moskowitz at 646-608-3726.

Protocol

22-170

Phase

I

Disease Status

Relapsed or Refractory

Investigator

Co-Investigators